Table 3.
Separate analysis of esophageal adenocarcinoma and esophageal cell carcinoma
| Esophageal adenocarcinoma | p Valuea | ||
|---|---|---|---|
| CROSS (n = 1544) | e-CROSS (n = 1074) | ||
| pCR, ypT0N0 | 259 (16.8) | 182 (16.9) | 0.908 |
| pCR, ypT0 | 298 (19.3) | 207 (19.3) | 0.986 |
| Resection | 0.457 | ||
| R0 | 1477 (95.7) | 1015 (94.5) | |
| R1 | 62 (4.0) | 51 (4.7) | |
| R2 | 2 (0.1) | 2 (0.2) | |
| Missing | 3 (0.2) | 4 (0.4) | |
| Postoperative morbidity | 881 (57.1) | 656 (61.1) | 0.042 |
| Postoperative mortality (< 30 days) | 44 (2.8) | 44 (4.1) | 0.090 |
| Esophageal squamous cell carcinoma | p Valuea | ||
|---|---|---|---|
| CROSS (n = 398) | e-CROSS (n = 285) | ||
| pCR, ypT0N0 | 192 (48.2) | 95 (33.3) | 0.000 |
| pCR, ypT0 | 221 (55.5) | 117 (41.1) | 0.000 |
| Resection | 0.229 | ||
| R0 | 384 (96.5) | 279 (97.9) | |
| R1 | 13 (3.3) | 4 (1.4) | |
| R2 | 1 (0.3) | 1 (0.4) | |
| Missing | 0 (0.0) | 1 (0.4) | |
| Postoperative morbidity | 252 (63.3) | 184 (64.6) | 0.738 |
| Postoperative mortality (< 30 days) | 18 (4.5) | 19 (6.7) | 0.227 |
Data are expressed as n (%)
Italics indicate the name of the main category
CROSS Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study, e-CROSS extended CROSS, pCR pathologic complete response, ypT0N0 pathologic complete response, ypT0 pathologic complete local response
aLikelihood ratio test